Natera, Inc. (NTRA)

Natera's stock price has been influenced by financial results, analyst ratings, and legal events. Q4 2025 results showed revenue growth and a gross margin of 66.9%, while Q1 2026 results also showed revenue growth, but a widening GAAP net loss caused a stock drop. Several analysts raised their price targets, but Wall Street Zen downgraded Natera to a "hold" rating. Insider selling has been noted. A Delaware federal judge awarded Natera a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales.

Natera experiences seasonality in demand, with the first quarter (Q1) typically being strong, as seen in Q1 2026 with record unit growth. The rapid adoption of new products like Fetal Focus also contributes to demand. The consistent strong performance in Q1 suggests a recurring seasonal uplift in demand during this period.

Natera, Inc. is a clinical genetic testing company specializing in non-invasive, cell-free DNA (cfDNA) testing technology, headquartered in Austin, Texas. The company operates within the healthcare sector, focusing on molecular diagnostics, genetic testing, oncology diagnostics, reproductive health screening, and transplant diagnostics. Natera's technology integrates molecular biology techniques with AI-powered bioinformatics. Natera's products span women's health, oncology, and organ health, including Panorama for prenatal testing, Signatera for cancer monitoring, and Prospera for transplant rejection assessment. Natera also provides Constellation, a cloud-based bioinformatics platform.

Natera's primary market is the United States, accounting for 97.69% of its 2024 revenues, with laboratory facilities in Austin, Texas, and San Carlos, California. The company also has an international presence, extending its reach globally through a cloud-based distribution model and a network of over 100 partners. International sales contributed 2% to revenues in 2024. Natera manages its EMEA expansion from Leiden, Netherlands, and plans to launch Signatera in Japan.

Natera's brand reputation has been positively influenced by advancements in genetic testing and strong clinical validation, supported by over 400 peer-reviewed publications. Positive interim analysis from Allogene Therapeutics' MRD-guided ALPHA3 trial and data suggesting Signatera MRD can identify breast cancer patients who may forgo surgery have contributed to this. The company also announced the commercial launch of Zenith™ Genomics for rare disease diagnosis.

Natera's ownership is predominantly held by institutional investors, including Vanguard Group Inc., BlackRock Inc., and T. Rowe Price Associates Inc. Individual investors hold a smaller percentage of the shares. Co-founders Matthew Rabinowitz and Jonathan Sheena held core technical and equity roles through the pre-IPO period, with Matthew Rabinowitz being the largest individual insider.